Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by HighField Biopharmaceuticals
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting
April 24, 2024
From
HighField Biopharmaceuticals
Via
Business Wire
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors
January 08, 2024
From
HighField Biopharmaceuticals
Via
Business Wire
HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers
December 18, 2023
From
HighField Biopharmaceuticals
Via
Business Wire
HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma
October 23, 2023
From
HighField Biopharmaceuticals
Via
Business Wire
HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
July 17, 2023
From
HighField Biopharmaceuticals
Via
Business Wire
HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers
June 13, 2023
From
HighField Biopharmaceuticals
Via
Business Wire
HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma
May 31, 2023
From
HighField Biopharmaceuticals
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.